Literature DB >> 8967954

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

R G Kurumbail1, A M Stevens, J K Gierse, J J McDonald, R A Stegeman, J Y Pak, D Gildehaus, J M Miyashiro, T D Penning, K Seibert, P C Isakson, W C Stallings.   

Abstract

Prostaglandins and glucocorticoids are potent mediators of inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) exert their effects by inhibition of prostaglandin production. The pharmacological target of NSAIDs is cyclooxygenase (COX, also known as PGH synthase), which catalyses the first committed step in arachidonic-acid metabolism. Two isoforms of the membrane protein COX are known: COX-1, which is constitutively expressed in most tissues, is responsible for the physiological production of prostaglandins; and COX-2, which is induced by cytokines, mitogens and endotoxins in inflammatory cells, is responsible for the elevated production of prostaglandins during inflammation. The structure of ovine COX-1 complexed with several NSAIDs has been determined. Here we report the structures of unliganded murine COX-2 and complexes with flurbiprofen, indomethacin and SC-558, a selective COX-2 inhibitor, determined at 3.0 to 2.5 A resolution. These structures explain the structural basis for the selective inhibition of COX-2, and demonstrate some of the conformational changes associated with time-dependent inhibition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8967954     DOI: 10.1038/384644a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  282 in total

1.  Implicit solvent model studies of the interactions of the influenza hemagglutinin fusion peptide with lipid bilayers.

Authors:  D Bechor; N Ben-Tal
Journal:  Biophys J       Date:  2001-02       Impact factor: 4.033

2.  Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).

Authors:  R García-Nieto; C Pérez; F Gago
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

3.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 4.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

5.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Authors:  M C Walker; R G Kurumbail; J R Kiefer; K T Moreland; C M Koboldt; P C Isakson; K Seibert; J K Gierse
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

Review 6.  Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways.

Authors:  C N Serhan; E Oliw
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 7.  COX in a crystal ball: current status and future promise of prostaglandin research.

Authors:  G A FitzGerald; P Loll
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 8.  Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?

Authors:  Timothy D Warner; Jane A Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

9.  Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action.

Authors:  Neetu Saini; Devinder Singh; Rajat Sandhir
Journal:  Metab Brain Dis       Date:  2019-01-02       Impact factor: 3.584

Review 10.  ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.

Authors:  Yan Gong; Zhongjie Fu; Raffael Liegl; Jing Chen; Ann Hellström; Lois Eh Smith
Journal:  Am J Clin Nutr       Date:  2017-05-17       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.